BACKGROUND: The Factor V Leiden (FVL) mutation is the commonest genetic abnormality associated with venous thromboembolism. AIMS: To determine the prevalence of the FVL mutation in Irish patients undergoing total hip replacement and whether it has an increased risk of deep venous thrombosis or pulmonary embolism (DVT/PE). METHODS: Prospective screening of 113 patients over 2 years. All had prophylaxis against thrombosis. Symptomatic DVT and PE were diagnosed with venography and ventilation-perfusion scans, respectively. RESULTS: The prevalence of the FVL mutation was 2%. Six patients (5.3%) developed a DVT/PE. Half of these had a history of venous thromboembolism (resulting in a higher risk of post operative DVT/PE (P = 0.04, Fischer's exact test) but none had the FVL mutation. Of the remaining 107 patients not developing DVT/PE, 2 had the FVL mutation (heterozygotes). CONCLUSIONS: The prevalence of the FVL mutation was 2% but was not a risk factor for acute symptomatic DVT/PE.
BACKGROUND: The Factor V Leiden (FVL) mutation is the commonest genetic abnormality associated with venous thromboembolism. AIMS: To determine the prevalence of the FVL mutation in Irish patients undergoing total hip replacement and whether it has an increased risk of deep venous thrombosis or pulmonary embolism (DVT/PE). METHODS: Prospective screening of 113 patients over 2 years. All had prophylaxis against thrombosis. Symptomatic DVT and PE were diagnosed with venography and ventilation-perfusion scans, respectively. RESULTS: The prevalence of the FVL mutation was 2%. Six patients (5.3%) developed a DVT/PE. Half of these had a history of venous thromboembolism (resulting in a higher risk of post operative DVT/PE (P = 0.04, Fischer's exact test) but none had the FVL mutation. Of the remaining 107 patients not developing DVT/PE, 2 had the FVL mutation (heterozygotes). CONCLUSIONS: The prevalence of the FVL mutation was 2% but was not a risk factor for acute symptomatic DVT/PE.
Authors: G D Lowe; F Haverkate; S G Thompson; R M Turner; R M Bertina; A G Turpie; P M Mannucci Journal: Thromb Haemost Date: 1999-06 Impact factor: 5.249
Authors: C S Philipp; A Dilley; P Saidi; B Evatt; H Austin; J Zawadsky; D Harwood; D Ellingsen; E Barnhart; D J Phillips; W C Hooper Journal: Thromb Haemost Date: 1998-12 Impact factor: 5.249
Authors: K Wåhlander; G Larson; T L Lindahl; C Andersson; L Frison; D Gustafsson; A Bylock; B I Eriksson Journal: Thromb Haemost Date: 2002-04 Impact factor: 5.249
Authors: J Voorberg; J Roelse; R Koopman; H Büller; F Berends; J W ten Cate; K Mertens; J A van Mourik Journal: Lancet Date: 1994-06-18 Impact factor: 79.321
Authors: Joanne E Joseph; Joyce Low; Brett Courtenay; Michael J Neil; Michael McGrath; David Ma Journal: Br J Haematol Date: 2005-04 Impact factor: 6.998